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Introduction: Deep venous thrombosis (DVT) resolution involves fibrinolysis, neovascularization, and fibrosis. We
hypothesized that promoting neovascularization would accelerate DVT resolution.
Methods: A rat model of stasis DVT was produced with proximal ligation of the inferior vena cava (IVC) and all visible
tributaries. Oneg of interferon inducible protein (IP-10; angiostatic chemokine), basic fibroblast growth factor (bFGF;
pro-angiogenic cytokine), epithelial neutrophil activating protein (ENA-78; pro-angiogenic chemokine), or saline
solution control was injected into the IVC after ligation, and then via tail vein injection daily until sacrifice at either 4 or
8 days. Peripheral blood counts were measured, and thrombus weight was recorded at sacrifice. Laser Doppler in vivo
imaging was used to estimate post-thrombotic IVC blood flow. Immunohistologic assessment of the thrombosed IVC for
polymorphonuclear neutrophils (PMNs), monocytes (ED-1), and laminin (neovascular channels) was performed or the
thrombus was separated from the IVC and assayed for keratinocyte cytokine (KC), monocyte chemotactic protein-1
(MCP-1), bFGF with enzyme-linked immunosorbent assay (ELISA), and total collagen with a direct colorimetric assay.
Results: Peripheral blood and intrathrombus PMNs and monocytes were not significantly different in the treated or
control rats. There were no differences in any measure at 4 days. At 8 days, thrombus neovascularity, but not weight or
collagen content, was increased in rats treated with bFGF or ENA-78 compared with control rats (17.6  0.93, 16.2 
0.97 vs 13.2 0.79; channels/5 high-power fields (hpf; n 6-10; P < .05). Post DVT IVC blood flow was significantly
increased in bFGF-treated rats but not in rats treated with IP-10 or ENA-78, as compared with control rats. Rats treated
with ENA-78 had increased intrathrombus bFGF compared with control rats (85 27 pg/mg protein vs 20 6 pg/mg
protein; n  6; P < .05), but other mediators were not significantly different in treated rats compared with control rats.
Conclusion: Pro-angiogenic compounds increase thrombus neovascularization, but this does not correlate with smaller or
less fibrotic DVT. Mechanisms other than neovascularization may be more important to hasten DVT dissolution. (J Vasc
Surg 2004;40:536-42.)
Clinical Relevance: Improved therapy for deep venous thrombosis (DVT) will ideally increase the rate of thrombus
dissolution and eliminate the bleeding risks of anticoagulation. This study evaluated promoting DVT neovascularization
with angiogenic chemokines, and, while successful by experimental measures, this did not translate into smaller DVT.
Solely promoting thrombus neovascularization will not likely speed resolution.Deep venous thrombosis (DVT) is a common condi-
tion, affecting approximately 250,000 patients per year and
responsible for 50,000 deaths per year.1 Anticoagulant
therapies are effective for prophylaxis and treatment,2 but
the risk for anticoagulation-related hemorrhagic complica-
tions and development of chronic venous insufficiency
(CVI) are significant over time. Angiogenesis, or neovascu-
larization, is now recognized as an important process in
many physiologic and disease states, including cancer, pe-
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doi:10.1016/j.jvs.2004.05.023536ripheral arterial vascular disease, and wound healing.3 In
the setting of a vascular occlusion such as DVT, it is logical
to assume that angiogenesis may have a significant effect on
the course of its resolution.4 Previous reports by our
group5-7 have demonstrated a sustained neovascular re-
sponse after experimental DVT and an apparent beneficial
effect on its resolution.
Chemokines are chemotactic cytokines that direct leu-
kocyte extravasation and activity.8 They can be subdivided
into cysteine-X-cysteine (CXC) and cysteine-cysteine fam-
ilies, members of which differ in their leukocyte specificities
but often share angiogenic activity. Pro-angiogenic CXC
chemokines have a specific peptide sequence, Glu-Leu-Arg
(ELR), which confers the neovascular activity.7 Growth
factors are small peptides that stimulate endothelial cell
proliferation and migration. Chemokines and growth fac-
tors are present during DVT resolution, and experimental
studies have demonstrated beneficial effects of the CXC
chemokine interleukin (IL)–8,5 the CC chemokine mono-
cyte chemotactic protein (MCP)–1,9 and the growth factor
vascular endothelial growth factor10 on DVT resolution.
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creases thrombus dissolution is unknown.
Clinically, promoting DVT resolution with or without
standard anticoagulation is attractive to decrease the risk for
pulmonary embolism and to minimize the sequelae of CVI.
Chemokines are attractive agents with pharmacologic po-
tential in many disease states.11 This study used therapeutic
administration of interferon inducible protein (IP-10), a
CXC ELR–negative angiostatic chemokine,12 basic fibro-
blast growth factor (bFGF), a pro-angiogenic factor10,13
and epithelial neutrophil activating protein (ENA-78), a
CXC ELR–positive pro-angiogenic chemokine,8,14 and
measures of resolution of DVT. These agents were chosen
because of their in vitro and in vivo activities, and the
relatively narrow spectrum of leukocytes affected.
METHODS
Study design and animal model. Male Sprague-
Dawley rats (350-450 g) were used in these studies.
Thrombosis was induced with proximal ligation of the
inferior vena cava (IVC) below the renal veins and ligation
of all visible tributaries, as described.5,6,15 A clot developed
in more than 90% of rats. Rats were sacrificed at 4 or 8 days.
At sacrifice the thrombosed IVC was exposed through the
previous incision and removed en bloc. A small consistent
portion was divided intact and preserved for histologic
analysis, while most of the specimen was divided into wall
and thrombus portions with blunt or sharp dissection. Only
the thrombus was then weighed and snap-frozen for later
biochemical analysis. All studies were approved by the
University of Michigan Committee on the Use and Care of
Animals and complied with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
Study agents. Control rats received normal saline so-
lution, and 3 experimental groups at each time point re-
ceived IP-10, bFGF, and ENA-78 (R&D). Six rats were
assigned to each group at the 4-day time point, and 10 rats
were assigned to each group at the 8-day time point. Rats
were given 1 g of the study agent daily in 0.1 mL of
normal saline solution with 1:500 bovine serum albumin,
with dosing extrapolated from other experimental stud-
ies.10,12,13 No specific pharmacokinetic studies were per-
formed. The study agent was first administered at the time
of IVC ligation, with injection of the agent directly into the
ligated IVC with a 30-gauge needle and cotton-tipped
applicator pressure for hemostasis. Subsequent doses were
given daily via tail vein injection until sacrifice.
Peripheral blood counts. A sample of arterial blood
was taken from the dorsal tail artery before both laparoto-
mies. Peripheral leukocyte quantification was determined
by means of automated peripheral blood differential (He-
mavet; CDC Technologies).
Laser Doppler scanning. A laser Doppler scanner
(Lisca) was used to assess in vivo microvascular IVC blood
flow, based on techniques as described.16 At laparotomy
the pre-IVC ligation, immediate post-ligation, and harvest
of the exposed IVC region of interest were scanned (5-
second scans with 30 seconds between, over 4 cycles).Depth was constant and adjusted for each rodent to ensure
the best estimation of the mid-coronal IVC section. These
scans were saved, and accompanying image software was
used to estimate the mean color flow. This was summed
and averaged for the 4 cycles. Mean intensity was deter-
mined for each rodent at the various time points, and
represents intra-IVC blood flow velocity, not volume flow.
The intensities were reported as percent of baseline flows
specific to each animal to ensure consistency (each served as
its own control).
Immunohistochemistry. The specimen harvested for
histologic analysis was imbedded in paraffin, sliced into
10-m sections, and stained as described.5,6,17 In brief, the
tissue was first deparaffinized and dehydrated through
graded alcohols, and nonspecific binding sites were blocked
with species-specific serum. The sections were then incu-
bated with either 1:1000 anti-neutrophil (polymorphonu-
clear neutrophil [PMN]) antibody (Accurate Chemical),
1:100 ED-1 antibody (Serotec) for monocytes, or 1:500
anti-laminin (Santa Cruz Biotechnology) for neovascular
channels.5,6 Species-specific secondary antibodies and ABC
kits (Vector Laboratories) were used according to the man-
ufacturer’s instructions to develop slides, and the slides
were then counterstained with hematoxylin and cover-
slipped. In a blinded fashion, positive-staining cells or
channels were counted in 5 randomly selected high-power
fields (hpf) around the vein wall-thrombus interface.
Enzyme-linked immunosorbent assays. Thrombi
were prepared for assays by homogenization, sonication
(30 seconds), and centrifugation (15 minutes  10,000g)
in buffer solution. Enzyme-linked immunosorbent assays
(ELISAs) were performed as described for keratinocyte
cytokine (KC, a CXC rodent IL-8 analogue), MCP-1, and
bFGF, with species-specific primary antibodies quantified
by using a double-ligand technique.5,15,17 Plates were read
at 450 nm. Total protein was quantified to account for
differing protein composition of samples. A modified Brad-
ford assay (Pierce) was performed using the homogenate
from ELISAs with serial dilutions of bovine serum albumin
as standards. Results are expressed as nanograms or pico-
grams per milligram of protein.
Collagen assay. Thrombus collagen content was esti-
mated with a commercially available kit (Bicolor LTD)
according to the manufacturer’s instructions. The Sircol
collagen assay is a colorimetric assay in which Sirius red dye
binds to the side chains of amino acids found in collagen.
Plates were read at 590 nm. Specimen preparation and
standardization of results were identical to those for
ELISAs; units are micrograms per milligram of clot.
Statistical analysis. Data from all 4 treatment groups
were compared with analysis of variance with the Bonfer-
roni correction for multiple comparisons. P  .05 was
considered significant, and all data are presented as mean
SEM.
RESULTS
Early experimental DVT resolution was not affected by
mediator administration.
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differences between groups at 4 days, consistent with the
notion that an angiogenic response develops later in the
course of thrombus resolution.6 The study agents were
generally tolerated well, and animal deaths did not exceed 2
in any study group.
Pro-angiogenic compounds increase thrombus neovas-
cularization. Thrombus neovascularization was estimated
by counting laminin-positive channels, as described.5 Neo-
vascular channels develop in the periphery of the thrombus
as part of the normal course of resolution in this model, and
laminin staining reliably identifies these channels. The
channels do not appear to invade the adventitia; rather,
they restrict themselves to within the thrombus. After 8
days the correlation between laminin and von Willebrand
factor staining is essentially identical.6 Similar sections of
thrombosed IVC were selected for consistency between
Fig 1. Neovascularization. A, Rats treated with pro-an
neutrophil activating protein (ENA-78) had significantly
*P  .05 treatment vs controls; P  .05, 8-day vs 4-day
hematoxylin counterstaining at 1000. IP-10, Interferogroups. At 4 days there were no differences in the number
of neovascular channels between any groups. At 8 days the
number of channels increased significantly in all groups (n
 5 per group; P .05 for all). Control rats had 13.2 0.8
channels/5 hpf, and IP-10–treated rats had a similar num-
ber of channels (11.6  0.5 channels/5 hpf). However,
rats treated with ENA-78 and bFGF demonstrated a 1.2-
fold and 1.3-fold increase, respectively, in neovascular
channels, compared with control rats (n 5 per group; P
.05 for both; Fig 1). Only exogenous bFGF increased
thrombus microvascular blood flow. Laser Doppler ultra-
sound enables detection of in vivo intrathrombus and peri-
thrombus blood flow through a thin plane in the throm-
bosed IVC, and is used in a similar manner to that described
for models of hind limb ischemia.16 Restoration of blood
flow after IVC ligation was quantified as a percentage of
baseline (pre-ligation) flow for that rat, enabling each rat to
nic basic fibroblast growth factor (bFGF) and epithelial
laminin-positive channels at 8 days (n 6-8 per group;
rgroup group). B, Representative section is shown with
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between groups. As with the neovascular channel counts,
all groups increased their percentage of blood flow from 4
days to 8 days (n  5-8; P  .05). In rats treated with
intravenous bFGF 93.5%  11.1% of pre-ligation blood
flow was restored at sacrifice, compared with 58.2% 6.2%
flow restoration in control rats (n  5-8; P  .05). There
were no significant differences in flow restoration among
rats treated with IP-10 (51.6% 2.3%) or ENA-78 (68.5%
 3.8%), compared with control rats (Fig 2).
Only bFGF was altered with angiogenic compound
administration. There were no significant differences be-
tween any treatment group at 4 days. However, at 8 days
rats treated with ENA-78 had an intrathrombus bFGF
concentration greater than that in control rats (85  27 vs
20  6 pg/mg protein; n  8; P  .05) and ENA-78–
treated rats at 4 days (27  4 pg/mg protein; n  5; P 
.05). Rats treated with bFGF had significantly greater in-
trathrombus bFGF at 8 days than at 4 days (26  11
pg/mg protein; n  5; P  .05), and showed a trend
toward increased intrathrombus bFGF concentration,
compared with control rats at 8 days (68  12 pg/mg
Fig 2. Laser Doppler scan. Intrathrombus blood flow (A
(bFGF), but was not affected by other compounds (n 6
vs 4-day intergroup group). Representative laser Dopple
8-day sacrifice in a control animal (D), and at 8-day sacri
protein; ENA-78, epithelial neutrophil activating proteinprotein; n  9; P  .12). There was no significant differ-
ence between control and IP-10–treated rats (24  6
pg/mg protein; n  6; P  NS; Fig 3). Similar levels of
intrathrombus KC and MCP-1 were found between the
groups at 8 days (KC: control, 0.62 0.49 ng/mg protein;
IP-10, 0.52  0.15 ng/mg protein; bFGF, 1.52  0.53
ng/mg protein; ENA-78, 0.16  0.12 ng/mg protein.
MCP-1: control, 8.38  5.1 ng/mg protein; IP-10, 5.74
 3.49 ng/mg protein; bFGF, 12.7 6.6 ng/mg protein;
ENA-78, 10.5  7.3 ng/mg protein; n  5; P  NS). No
significant levels of any exogenous growth factor or chemo-
kines were found in serum samples at harvest (data not
shown).
Pro-angiogenic compounds did not affect intrathrom-
bus leukocyte differential. Intrathrombus neutrophils were
quantified at immunohistochemistry, and were not differ-
ent between control rats (14.8  1.5) or rats treated with
IP-10 (15.6 1.0), bFGF (16 1.5), or ENA-78 (18.4
0.9) at 8 days. Intrathrombus monocytes (ED-1–positive)
were also not significantly different between any of the
groups at either time point (4 days: control, 46.7  2.7;
IP-10, 50.2  2.2; bFGF, 49.7  1.9; ENA-78, 45.7 
greater in rats treated with basic fibroblast growth factor
r group; *P .05, treatment vs controls; P .05, 8-day
ges are shown before ligation (B), after ligation (C), at
a bFGF-treated animal (E). IP-10, Interferon inducible
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40.4  3.8; ENA-78, 43.6  1.4). Similarly, though
intrathrombus PMNs were approximately 3-fold greater at
4 days than at 8 days, no significant difference was found
between the treatment groups at 4 days (control, 42.7 
2.2; IP-10, 4.08 3.9; bFGF, 37 3.8; ENA-78, 46.7
5.8; all cells/5 hpf; n  6-8; P  NS).
Pro-angiogenic compounds did not affect overall DVT
dissolution or fibrosis. Thrombus weight is a gross but
reliable measure of thrombus dissolution.5,17 Though the
thrombus weight of control rats (17.7  5.0 mg) trended
larger than in treated rats, these differences did not reach
significance (Fig 4). Thrombus collagen turnover occurs as
the thrombus ages, and is influenced by clot duration and
leukocytes present. Thrombus collagen content did not
differ between control rats (2.25  1.2 g/mg clot) and
rats treated with IP-10 (1.5 0.53 g/mg clot; P .58),
bFGF (1.83 1.6 g/mg clot; P .83), or ENA-78 (2.2
 2.2 g/mg clot; P  .98).
DISCUSSION
Neovascularization is a well-established event in most
wound healing processes, of which DVT resolution is a
typical example.3,4 Restoration of blood flow through a
clot has been identified in the earliest descriptions of venous
thrombus resolution4,18 and other mechanisms of throm-
bus resolution, such as leukocyte-derived plasminogen ac-
tivation, have been linked to this neovascular response.19-21
This report suggests that, although increasing thrombus
neovascularization is possible with pro-angiogenic com-
pounds such as ELR-positive CXC chemokine ENA-78 or
the growth factor bFGF, no increase in DVT dissolution
was coincidentally observed. Furthermore, that only bFGF
increased physiologic blood flow (at laser Doppler scan-
ning) suggests a disconnect between thrombus neovascular
Fig 3. Basic fibroblast growth factor (bFGF) concentration. bFGF
was quantified with an enzyme-linked immunosorbent assay
(ELISA) and normalized to total protein. Rats treated with epithe-
lial neutrophil activating protein (ENA-78) had significantly
greater intrathrombus bFGF at ELISA than control rats did at 8
days, whereas rats treated with bFGF showed a trend toward
higher intrathrombus bFGF (n  6-10 per group; *P  .05 vs
8-day controls; P .05, 8-day vs 4-day intergroup group compar-
ison). IP-10, Interferon inducible protein.channel number and intrathrombus and perithrombus
blood flow. It may be that the channel size is more impor-
tant than the absolute number, but this is difficult to
quantify. From previous studies, most resumption of blood
flow after DVT occurs between the thrombus–vein wall
interface as it retracts, and not within the thrombus it-
self.5,6,15 Thus bFGF may cause greater functional throm-
bus contraction, consistent with its extra-angiogenic activ-
ities,22 despite thrombus collagen not being significantly
increased. Furthermore, altered neovascularization was
probably related to the direct activity of these agents on
leukocytes or matrix cells, not by chemoattractant activities,
inasmuch as no difference in leukocyte type or number, or
increase in common PMN-associated (KC) or monocyte-
associated (MCP-1) mediators was observed.
Neutrophils are the predominant early leukocytes in
DVT,23 and mediate angiogenesis in a variety of settings.
The PMN chemokine IL-8 has been associated with angio-
genesis in diseases in human beings.5,24 In these studies
PMN recruitment and angiogenesis were both mediated by
IL-8, and angiogenesis was seen after an increase in leuko-
cytes had taken place. The specific contributions of neutro-
phil influx and angiogenesis are undefined, but have re-
cently been partially elucidated in studies of neutrophil
depletion.15 For example, PMN depletion is associated
with larger thrombi and greater thrombus collagen con-
tent, whereas IL-8 supplementation is associated with
smaller thrombi coincident with increased neovasculariza-
tion.5 While adversely affecting thrombus resolution, PMN
depletion does not appear to have any effect on develop-
ment on neovascular channels or in vitro angiogenic activ-
ity (Henke, unpublished data). Indeed, other investigators
have noted that neutropenia does not impair wound heal-
ing.25 As shown in the current study, ENA-78 increased
intrathrombus bFGF levels significantly, possibly through
stimulation of PMN vascular growth factor production.26
Fig 4. Thrombus weight. Thrombus was weighed and measured
immediately after sacrifice. There were no significant differences
between any groups at the 4-day or 8-day time point. However, in
all groups thrombi were smaller at the 8-day time point compared
with the 4-day time point (n 8-10 per group; *P .05, 8-day vs
4-day intergroup group comparison). IP-10, Interferon inducible
protein; bFGF, basic fibroblast growth factor; ENA-78, epithelial
neutrophil activating protein.
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same increase in perithrombus blood flow that exogenous
bFGF did. Similarly, that ENA-78 increased thrombus
neovascularization may have been secondary to its effect of
increasing local bFGF rather than to its primary pro-angio-
genic activity, because most data regarding this compound
are from pathologic disease states, such as neoplasia.3,14
Monocyte and macrophage influx has also been de-
scribed as essential for angiogenesis.27,28 Indeed, some
investigators have hypothesized that macrophage influx
may be significantly more important than neutrophil influx
in mediating angiogenesis,29 which further supports the
notion that the detrimental effects of neutropenia are not
due to inhibition of angiogenesis. The agents administered
in our studies did not affect monocyte or macrophage
influx, but do have monocyte activating properties.14
Other experimental studies of DVT have noted that mono-
cyte influx specifically is associated with improved throm-
bus resolution30 and that exogenous MCP-1 improves
thrombus resolution.9 Neither of these findings is contra-
dicted by our studies, and the notion that these effects are
due to monocyte influx stimulated with chemokines or
growth factors is further supported.
Thrombus dissolution occurs via fibrinolysis and fibro-
sis to produce intraluminal scar. While bFGF may stimulate
collagen production, that no total increase in thrombus
collagen was found argues that it may promote collagen
maturation, increase cross-linking, or increase myofibro-
blast influx.3,22 Neither IP-10 nor ENA-78 have specific
pro-fibrotic properties, unlike other chemokines such as
MCP-1, which was not significantly altered with the treat-
ments, and is consistent with the findings of the current
study.27 Also consistent with the lack of difference in
thrombus collagen was the lack of difference in DVT
weights, though this interrelation has not been proportion-
ate in other studies with the same basic model.17,31 In
assessing these studies our group has considered thrombus
weight to be the most important measure of resolution,
inferring that decreased thrombus burden will diminish the
risk for sequelae such as pulmonary embolism or CVI. The
interrelation of fibrosis and neovascularization is conflict-
ing. Studies of pulmonary fibrosis32 suggest a positive
association, while inhibiting neovascularization in a
wound-healing model was not associated with decreased
local collagen levels.33 Of note, surgical trauma from IVC
ligation appears to make little contribution to this fibrotic
process (unpublished data).
Limitations of the current study are that the angiogenic
compounds tested, while having documented strong activ-
ities in vitro and in vivo, have other leukocyte activation
properties that may confound the overall angiogenic bal-
ance. For example, ENA-78 is a PMN activator that causes
release of proteases that may break down natural fibrino-
lytic proteins, and IP-10, primarily a lymphocyte chemoat-
tractant, exerts its angiostatic effect via CXCR3 recep-
tors,14 which may not have been present on intrathrombus
cells. Furthermore, lymphocytes appear to be important in
thrombus resolution after 14 days. Current studies in amouse model indicate that the early response is primarily of
the Th1 response, which supports the generalized inflam-
matory response to thrombosis, and a later Th2 response,
which has a less clear role (unpublished data). No attempt
was made to label the infused agents to confirm thrombus
distribution, because previous venography data suggested
the primary route of tail vein is to the IVC, even with an
occlusion present.15 While increased intrathrombus PMN
would be empirically expected in the ENA-78–treated
group, it may be that this increased PMN influx occurred
before harvest (eg, at around 2 days) and was not detected
at these later time points. Consistent with this observation
is our previous study that showed no significant increase in
8-day PMN influx with exogenous IL-8 administration.5
This study also cannot conclude the converse, that is, that
neovascularization inhibition does not impair DVT resolu-
tion, because no isolated angiostatic agent was tested.
Endostatin has powerful angiogenic inhibitory effects, but
in settings other than neoplasia, such as wound healing,33 it
has had mixed results and is costly to procure experimen-
tally. Last, vascular endothelial growth factor was not mea-
sured in this model system, because previous experiments
suggest that this is a less important mediator than bFGF.5
Clinically, the more complete the DVT resolution the
less likelihood of development of CVI.34 Our study has
shown that venous thrombus neovascularization can be
increased by pro-angiogenic compounds that do not affect
leukocyte influx or inflammatory activity, as measured by
prototypical chemokine levels, but do not appear to de-
crease thrombus size. Further work is needed to clarify the
basic mechanisms of thrombus resolution, with the aim of
accelerating thrombolysis with minimal systemic bleeding
risk, and countered against the need for firm adhesion of
the residual thrombus to prevent pulmonary embolism.
We thank D. Segur for administrative assistance.
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